Celgene Announces Revlimid Maintenance Therapy Showed Statistical Significance Reduction, Says MEL200 Showed Longer Median PFS, OS vs MPR

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation(NASDAQ: CELG), today announced data from a study comparing melphalan,prednisone and REVLIMID (lenalidomide) (MPR) with high-dose chemotherapy andtandem autologous stem cell transplant (MEL200), as well as evaluating theeffect of lenalidomide maintenance in patients with newly-diagnosed multiplemyeloma were presented during a June 3^rd oral session at the American Societyof Clinical Oncology (ASCO) 2013 Annual Meeting in Chicago, Ill.In the study, conducted by the Gruppo Italiano Malattie EMatologichedell'Adulto (GIMEMA), and presented by lead investigator, Prof. AntonioPalumbo, Chief of the Myeloma Unit, Department of Oncology, at the Universityof Torino, a total of 402 patients received four 28-day courses oflenalidomide and low-dose dexamethasone at diagnosis, and then were randomlyassigned to receive six cycles of MPR (n=202) or MEL200 (n=200), and toreceive either continuous lenalidomide maintenance treatment or to be followedby observation.After a median follow-up of 49 months from diagnosis, median progression-freesurvival (PFS), the primary endpoint of the study, was 24 months with MPRcompared to 38 months with MEL200 (HR 1.69, p